Ironwood IPO Raises Plenty Of Cash And Plenty Of Questions For Biotech Investors
The much-anticipated debut of the constipation-drug developer hits $188 million, but a venture owner had to buy nearly half the issue.
The much-anticipated debut of the constipation-drug developer hits $188 million, but a venture owner had to buy nearly half the issue.